Page last updated: 2024-12-07

1,(n2)-ethenoguanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

You're likely referring to **1-(N2-ethenoguanine)**, also known as **ε-guanine** or **ethenoguanine**.

Here's a breakdown:

**What it is:**

* **Structure:** 1-(N2-ethenoguanine) is a modified guanine base, a component of DNA and RNA. It's formed by the addition of an ethano bridge between the N2 and C8 positions of guanine.
* **Formation:** This modification arises due to exposure to various environmental mutagens, including vinyl chloride, acetaldehyde, and other reactive aldehydes.

**Importance in Research:**

1. **Carcinogenesis and Mutagenesis:**
* 1-(N2-ethenoguanine) is a **mutagenic lesion**, meaning it can cause changes in DNA sequence. It can lead to G:C to A:T transitions, which are associated with various cancers.
* This modification is found in both human and animal tissues and is linked to various types of cancers, including liver, bladder, lung, and colon cancer.

2. **Biomarker of Exposure:**
* The presence of 1-(N2-ethenoguanine) in DNA can be used as a **biomarker** to detect exposure to environmental mutagens. This helps researchers study the link between exposure and disease risk.

3. **DNA Repair Mechanisms:**
* Understanding how cells repair 1-(N2-ethenoguanine) lesions is crucial for developing strategies to prevent cancer. Researchers are investigating DNA repair pathways involved in removing this modification.

4. **Drug Development:**
* The study of 1-(N2-ethenoguanine) can contribute to the development of new drugs that target the formation of this lesion or enhance its repair mechanisms.

**Overall:**

1-(N2-ethenoguanine) is a significant area of research due to its role in mutagenesis, carcinogenesis, and the development of cancer prevention strategies. It's a key player in understanding the impact of environmental mutagens on human health.

1,(N2)-ethenoguanine: formed from 2-halooxiranes; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,N(2)-ethenoguanine : A nucleobase analogue obtained by addition of an etheno group across positions 1 and N2 of guanine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID124322
CHEBI ID134096
SCHEMBL ID8148622
SCHEMBL ID1576524
MeSH IDM0226958

Synonyms (15)

Synonym
1,(n2)-ethenoguanine
1,n(2)-ethenoguanine
56287-13-9
1,n(2)-epsilong
1,4-dihydro-9h-imidazo[1,2-a]purin-9-one
CHEBI:134096
1,4-dihydroimidazo[1,2-a]purin-9-one
1,4-dihydro-9h-imidazo(1,2-a)purin-9-one
9h-imidazo(1,2-a)purin-9-one, 1,4-dihydro-
1,n2-epsilong nucleobase
SCHEMBL8148622
SCHEMBL1576524
DTXSID60204825
epsilong
3,9-dihydro-9-oxo-5h-imidazo[1,2-a]purine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
imidazopurine
nucleobase analogueA molecule that can substitute for a normal nucleobase in nucleic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (21.43)18.2507
2000's8 (57.14)29.6817
2010's1 (7.14)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.85 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]